Background Transarterial embolization (TAE) is increasingly used across a broad spectrum of musculoskeletal conditions, ranging from established hemostatic and tumor-related indications to emerging pain-directed procedures for degenerative joint disease and chronic inflammatory tendinopathies. Because these applications differ substantially in clinical maturity, methodological quality, durability of outcomes, and comparative evidence, an indication-stratified synthesis is needed. Main body This narrative review summarizes technical principles, vascular anatomy considerations, embolic agent selection, clinical indications, and evidence maturity in musculoskeletal TAE. Hemostatic and selected tumor-related applications are established components of multidisciplinary care, whereas pain-directed embolization, including Genicular artery embolization for knee osteoarthritis and embolization for tendinopathies, is generally performed as a stand-alone minimally invasive procedure targeting pathological neovascularity. Current evidence remains heterogeneous, with variable study designs, follow-up, endpoints, and definitions of technical and clinical success. Conclusions Musculoskeletal TAE is an expanding field with established, intermediate, and exploratory indications. Its evidence base is strongest for hemostatic and selected tumor-related applications, whereas stand-alone pain-directed embolization requires careful patient selection, standardized outcome assessment, and further comparative trials to define durability and clinical value.
No takes yet. Share an insight, caveat, or question.
Pelage et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: